Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1892 Target Snapshot

Glutamate carboxypeptidase 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
658Compounds
129Assays
4Approved Drugs
765.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Glutamate carboxypeptidase 2 shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q04609. Start with prostate cancer, then reuse UniProt Q04609 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with prostate cancer, then reuse UniProt Q04609 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
prostate cancer

Glutamate carboxypeptidase 2 shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with prostate cancer because it currently carries approved-linked support. Linked drugs include HUJ591 111IN, HUJ591 177LU, J591 177LU, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate carboxypeptidase 2 as ChEMBL target CHEMBL1892, mapped to UniProt Q04609. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate carboxypeptidase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1892
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q04609
Glutamate carboxypeptidase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate carboxypeptidase 2 is the right protein anchor across sources, using UniProt Q04609 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why prostate cancer is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlutamate carboxypeptidase 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ04609
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate carboxypeptidase 2
UniProt AccessionQ04609
Component TypeProtein
Sequence Length750 aa

Glutamate carboxypeptidase 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glutamate carboxypeptidase 2, mapped to UniProt Q04609. Sequence length is 750 aa.

Mapped IDQ04609
Review nameGlutamate carboxypeptidase 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Glutamate carboxypeptidase 2 shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
prostate cancer
5 linked drugs · 5 direct · 5 efficacy
Linked drugHUJ591 111IN
Linked drugHUJ591 177LU
Linked drugJ591 177LU
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Approved-linked Approved
prostate neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Late clinical Phase III
prostate adenocarcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Linked drugMLN-2704
Late clinical Phase III
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Late clinical Phase III
prostate carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Clinical signal Phase II
adenoid cystic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with prostate cancer because it currently carries approved-linked support. Linked drugs include HUJ591 111IN, HUJ591 177LU, J591 177LU, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseprostate cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
3
Phase II
1
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC50366.0
KI326.0
EC505.0
KD68.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL6007312 11.0 Ki 0.01 Preclinical
CHEMBL510924 11.0 Ki 0.01 Preclinical
CHEMBL5866602 10.77 Ki 0.017 Preclinical
CHEMBL3578202 10.74 Ki 0.018 Approved
CHEMBL5786057 10.7 Ki 0.02 Preclinical
CHEMBL510924 10.68 IC50 0.021 Preclinical
CHEMBL5994140 10.52 Ki 0.03 Preclinical
CHEMBL5848906 10.46 Ki 0.035 Preclinical
CHEMBL6010838 10.44 Ki 0.036 Preclinical
CHEMBL3309678 10.35 Ki 0.0449 Preclinical
Distribution

pChEMBL Value Distribution

26
5.0
50
5.5
46
6.0
74
6.5
83
7.0
104
7.5
68
8.0
70
8.5
71
9.0
39
9.5
pChEMBL
Approved Drugs

Approved Drugs

PIFLUFOLASTAT
CHEMBL4299851
Approved 2021
Properties Compare Identifier
GOZETOTIDE
CHEMBL3578202
Approved 2020
Properties Compare Identifier
Assay Landscape

Assay Landscape

129
Total Assays
556
Tested Compounds
3
Assay Types
Binding — 121 assays, 556 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 65 158 7.8
single protein format 54 373 7.6
subcellular format 1 25 7.2
tissue-based format 1 0 —
ADME — 7 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 0 —
Functional — 1 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 6 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine